Dr Martens sales surge as bootmaker shrugs off inflation

The footwear brand saw shares jump by a quarter in early trading.
Dr Martens shop (Lauren Hurley/PA)
PA Archive

Dr Martens has shrugged off soaring inflationary pressure to raise its sales guidance for the year.

Shares in the bootmaker jumped by a quarter in early trading after the company said consumer demand remained buoyant despite the challenging economic backdrop.

The historic British brand, which floated on the stock market last year, said that revenues increased by 18% to £908.3 million in the year to March 31, compared with the previous year.

Meanwhile, the group posted a £214.3 million pre-tax profit for the year, leaping from a £69.7 million profit in 2021.

The brand plans to open up to 35 new stores over the next year (Jane Barlow/PA)
PA Archive

Dr Martens said this sale momentum has carried into the new financial year and it now expects “high teens” growth in revenues for 2022-23.

It added that revenues and profitability will benefit from an increase in price in July, which will offset cost inflation.

Kenny Wilson, chief executive officer, told PA: “The price of making our products for the next seasons has gone up by 6%.

“We’ve decided that there will therefore be a price increase of 6% in July, our first increase in more than two years.

“The increase is purely to offset inflation. We are absolutely aware of the pressures on our customers right now and wouldn’t do this unless we thought it was necessary to maintain quality.”

The group said it opened 24 stores over the past year and expects to accelerate this to between 25 and 35 stores in the current financial year.

Dr Martens said the growth plan will focus on new stores in the US, as well as further sites in Italy and Germany.

Mr Wilson added: “We have always said that driving brand equity is our first priority, as it will ensure sustainable growth in the decades ahead.

“Our recent comprehensive brand survey shows that our brand is stronger than ever, with significant growth in awareness, familiarity and recent purchase.

“Dr Martens remains incredibly underpenetrated globally, giving us conviction in our future growth ambition.”

Shares in the company were 26.2% higher at 273.2p in early trading.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Sign up you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy notice .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in